Form 4: Apimeds Director Kogan Granted 3,000 Stock Options

Apimeds Pharmaceuticals US, Inc. director Elona Kogan was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Summary

• Elona Kogan, a Director of Apimeds Pharmaceuticals US, Inc. (APUS), was granted 3,000 stock options.
• The stock options have an exercise price of $1.92 per share.
• The transaction date for the option grant was October 15, 2025.
• The options expire on October 15, 2035.
• The shares underlying the option are common stock, par value $0.01 per share.
• The options will vest in quarterly installments beginning October 1, 2025, becoming fully vested after three years, contingent on continued service.
• Exercisability of the options is subject to stockholder approval of an amendment to the issuer's incentive plan to increase the number of shares available for issuance.
• The options will vest in full upon the occurrence of a Change in Control, as defined in the Plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options aligns the director's interests with shareholders and is a standard compensation practice. The contingency on stockholder approval introduces a minor element of uncertainty for the recipient, but it's a procedural step.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The options have a long expiration date (10 years), providing ample time for potential value realization.

Risks

• The exercisability of the granted stock options is contingent on obtaining stockholder approval for an amendment to the company's incentive plan to increase available shares, posing a risk to the recipient if approval is not secured.

Future Outlook

The future exercisability of the granted options is dependent on stockholder approval of an amendment to the company's incentive plan to increase the number of shares available for issuance. The options are designed to vest over a three-year period, subject to continued service.

Industry Context

The grant of stock options to a director is a common practice in the pharmaceutical and broader corporate sectors, serving as a key component of executive and director compensation packages to align leadership incentives with company performance and shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across industries, including pharmaceuticals, to incentivize long-term commitment and performance.
• The vesting schedule over three years is typical for equity grants, promoting retention and sustained contribution.
• The requirement for stockholder approval for incentive plan amendments is a standard corporate governance practice, ensuring shareholder oversight of equity compensation programs.

Corporate Governance

Related Party Transactions

• The grant of stock options to Elona Kogan, a Director, constitutes a compensation arrangement between the company and a related party.

Stakeholder Impact

• Shareholders will be impacted by the need to vote on an amendment to the incentive plan, which could potentially lead to dilution if approved.
• The director, Elona Kogan, is directly impacted by the grant, which serves as a significant component of her compensation and aligns her financial interests with the company's performance.

Next Steps

• The company will need to seek stockholder approval for an amendment to its incentive plan to increase the number of shares available for issuance, which is a prerequisite for the options to become exercisable.

Key Dates

Keywords

Apimeds Pharmaceuticals, APUS, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Grant, Vesting Schedule